Skip to main content
Clinical Trials/NCT05724901
NCT05724901
Completed
Not Applicable

A Wearable Remote Data Capture Solution for Home-Based Gait Assessment in Multiple Sclerosis

NYU Langone Health1 site in 1 country30 target enrollmentJanuary 11, 2023

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Multiple Sclerosis
Sponsor
NYU Langone Health
Enrollment
30
Locations
1
Primary Endpoint
Mean Gait Velocity
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The goal of this study is to validate an MS Gait Remote Capture and Analysis (MS-GRCA) system based on wearable shoe-based motion sensors for home-based and repeatable gait assessments.

Detailed Description

This is a single-site observational longitudinal study to validate an MS Gait Remote Capture and Analysis system for home-based and repeatable gait assessments. The investigators will recruit 30 participants who will have an in-person baseline visit (informed consent, standard gait assessment, sensor-based gait assessment, self-reported questionnaires), followed by three remote visits (sensor-based gait assessment, SUS questionnaire \[last remote visit only\]).

Registry
clinicaltrials.gov
Start Date
January 11, 2023
End Date
January 4, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Ages 18-70 years old (inclusive)
  • Confirmed diagnosis of MS (any MS subtypes, Relapsing Remitting \[RR\], Primary Progressive \[PP\], or Secondary Progressive \[SP\])
  • PDSS score from 0 to 5
  • Stable and continuous access to internet at home
  • Adequate home facilities (enough space, quiet and distraction free area)
  • Ability to provide informed consent.

Exclusion Criteria

  • Below average estimated premorbid cognitive functioning (based on WRAT-4 reading recognition standard z-score \< 85).
  • Presence of severe cognitive impairment (based on SDMT age normative z-score \< -3.0).
  • Presence of primary neurological disorders other than MS or primary psychiatric disorder that would influence ability to complete assessments.

Outcomes

Primary Outcomes

Mean Gait Velocity

Time Frame: Up to Week 4

Measured using sensor-based gait assessment

Secondary Outcomes

  • Mean Double Support Duration(Up to Week 4)
  • Mean Cadence(Up to Week 4)
  • Mean Stride Length(Up to Week 4)
  • Mean Stance Duration(Up to Week 4)

Study Sites (1)

Loading locations...

Similar Trials